IRADIMED CORP IRMD

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus Nasdaq

IRADIMED CORPORATION ("IRadimed", the "Company," "we," "us," "our" or similar terms) develops, manufactures, markets and distributes Magnetic Resonance Imaging ("MRI") compatible medical devices and related accessories, disposables and services relating to them. We were originally incorporated in Oklahoma under the name IRI Development, Inc. in 1992, and we merged our Oklahoma corporation into the newly formed Delaware corporation, IRADIMED CORPORATION, in April 2014.

We are the only known provider of a non-magnetic intravenous ("IV") infusion pump system that is specifically designed to be safe for use during MRI procedures and operates dependably in magnetic fields up to 15,000 gauss. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium 3870 MRI Compatible IV Infusion Pump System, introduced in 2025, has been designed with a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, touch screen user interface, and other special features to safely and predictably deliver anesthesia and other critical care IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated to remain immobile during an MRI scan.

Last close 83.45 2026-09-04
Market cap $1.07B 2026-06-30 share count
52-week range 67.84 - 107.90

Valuation FY2025 figures against the last close

P/S12.7x
P/E47.7x
P/FCF62.1x
EV/EBITDA39.1x
Dividend yield1.4%
Diluted EPS1.75

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $83.8M$73.2M$65.6M$53.3M$41.8M$31.7M$38.5M$30.4M$23.1M$32.5M
Cost of revenue $19.5M$16.9M$15.4M$12.0M$9.8M$8.1M$8.8M$7.2M$5.6M$6.2M
Gross profit $64.3M$56.4M$50.2M$41.3M$32.0M$23.6M$29.7M$23.2M$17.5M$26.3M
R&D $3.0M$2.8M$2.9M$2.3M$1.9M$1.9M$1.4M$1.5M$1.7M$1.3M
SG&A $17.8M$15.9M$15.1M$10.7M$9.8M$12.3M$10.5M$8.7M$9.0M$8.8M
Total operating expenses $38.2M$34.4M$30.1M$25.7M$22.2M$24.3M$21.1M$17.2M$16.2M$15.4M
Operating income $26.1M$22.0M$20.0M$15.6M$9.8M-$756.1K$8.6M$6.0M$1.3M$10.9M
Pre-tax income $28.4M$24.3M$21.7M$16.2M$9.8M-$616.9K$9.0M$6.2M$1.4M$11.0M
Income tax $5.9M$5.0M$4.5M$3.4M$510.8K$2.0M$587.6K$106.1K$896.6K$3.7M
Net income $22.5M$19.2M$17.2M$12.8M$9.3M$1.4M$9.6M$6.3M$499.8K$7.2M
EPS, basic 1.771.521.361.020.760.110.850.590.050.67
EPS, diluted 1.751.501.351.020.740.110.780.520.040.60
Shares, diluted (wtd. avg.) $12.9M$12.8M$12.7M$12.6M$12.6M$12.4M$12.3M$12.1M$11.7M$12.0M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $51.2M$52.2M$49.8M$58.0M$62.0M$50.1M$43.5M$28.0M$18.2M$17.7M
Receivables $13.7M$10.6M$12.2M$13.3M$5.1M$4.6M$7.3M$4.2M$3.8M$3.8M
Inventory $11.6M$10.4M$12.8M$5.4M$4.3M$3.9M$3.6M$4.1M$4.2M$3.9M
Total current assets $81.2M$75.2M$76.0M$77.5M$76.2M$63.7M$59.0M$44.5M$35.1M$33.9M
Property, plant and equipment $23.9M$16.8M$9.3M$2.4M$2.1M$2.1M$2.1M$1.9M$1.9M$1.5M
Other intangibles $3.4M$3.1M$2.5M$2.1M$1.1M$960.9K$860.1K$832.5K$885.5K$918.7K
Total assets $108.8M$98.3M$92.2M$85.5M$82.9M$71.1M$66.7M$48.4M$39.0M$37.2M
Accounts payable $1.8M$1.9M$1.9M$1.8M$782.9K$657.1K$993.7K$772.5K$656.7K$1.1M
Total current liabilities $10.2M$8.5M$16.3M$8.6M$6.8M$4.9M$5.9M$4.7M$4.1M$3.7M
Total liabilities $14.2M$11.5M$20.7M$11.8M$10.7M$9.7M$11.2M$6.5M$6.1M$5.3M
Retained earnings $64.2M$56.8M$43.3M$47.3M$47.0M$37.7M$36.3M$26.7M$20.4M$19.9M
Total equity $94.6M$86.8M$71.4M$73.7M$72.2M$61.4M$55.5M$41.9M$32.9M$31.9M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $24.9M$25.6M$13.5M$10.0M$11.3M$5.8M$10.2M$7.4M$3.4M$9.4M
Depreciation and amortisation $1.2M$818.0K$765.2K$670.7K$1.4M$1.3M$1.2M$1.1M$1.3M$955.8K
Stock-based compensation $2.9M$2.5M$2.2M$1.4M$1.5M$4.0M$1.9M$1.8M$2.5M$1.8M
Capital expenditure $7.8M$8.0M$7.4M$823.0K$482.3K$443.0K$368.3K$228.3K$775.6K$780.8K
Investing cash flow -$8.4M-$8.8M-$8.0M-$1.4M$648.2K$247.0K$3.2M$1.5M-$1.0M-$1.9M
Financing cash flow -$17.6M-$14.3M-$13.7M-$12.7M$24.4K$522.5K$2.0M$929.9K-$1.9M-$9.1M
Dividends paid $15.0M$13.7M$13.2M$12.6M
Buybacks $1.8M$10.0M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-028903.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $116.27B 36.1x 11.2%
MMM 3M CO $86.93B 28.1x 1.5%
BSX BOSTON SCIENTIFIC CORP $69.27B 24.6x 19.9%
BDX BECTON DICKINSON & CO $50.32B 31.7x 8.2%
DXCM DEXCOM INC $33.17B 42.1x 15.6%
RMD RESMED INC $32.94B 21.9x 9.9%
MDLN Medline Inc. $31.35B 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $23.93B 50.1x 6.3%